Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: March 2015 (Specifically dated March 19, 2015)
Context: This filing serves as a Director Declaration in conformity with Listing Rule 9.6.14, notifying the market of a change in directorship.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding corporate governance and does not contain financial statements or performance data.
Material Changes
Director Appointment: Dr. Daniel Podolsky, a Non-Executive Director of GSK, has been appointed as a Director to the Board of Agilent Technologies Inc.
Effective Date: July 21, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director appointment.
Key Facts for Investor Verification
- Verify the effective date of Dr. Daniel Podolsky's appointment to the Agilent Technologies Inc. board (July 21, 2015).
- Confirm that this filing is a governance notification and does not contain updated financial results for the period ending March 2015.
- Check for potential conflicts of interest or strategic implications arising from a GSK director joining a competitor or partner board (Agilent Technologies).